Imago Biosciences
329 Oyster Point Blvd, 3rd Floor
South San Francisco
CA
94080
United States
Tel: 415-529-5055
Website: http://imagobio.com/
39 articles about Imago Biosciences
-
Imago BioSciences Reports First Quarter 2022 Financial Results and Provides Recent Business Updates
5/12/2022
Imago BioSciences, Inc. reported financial results for the first quarter ended March 31, 2022 and provided a corporate update.
-
Imago BioSciences Announces Upcoming Presentations on Updated Data from Phase 2 Studies of Bomedemstat for the Treatment of Essential Thrombocythemia and Myelofibrosis at the 27th Congress of the European Hematology Association (EHA) for 2022
5/12/2022
Imago BioSciences, Inc. (“Imago”) (Nasdaq: IMGO), a clinical stage biopharmaceutical company discovering and developing new medicines for the treatment of myeloproliferative neoplasms (MPNs) and other bone marrow diseases, today announced that updated Phase 2 data from its two clinical programs for bomedemstat (IMG-7289) have been accepted for poster presentation at the 27th Congress of the European Hematology Association for 2022.
-
Imago BioSciences Announces First Participant Dosed in Investigator-Sponsored Study of Bomedemstat in Combination with Atezolizumab in Small Cell Lung Cancer
5/9/2022
Imago BioSciences, Inc. (“Imago”) (Nasdaq: IMGO), today announced that the first participant has been treated in an investigator-sponsored Phase 1/2 study of bomedemstat in combination with atezolizumab (Tencentriq®) during the maintenance phase of treatment in people newly diagnosed with extensive stage small cell lung cancer (ES-SCLC).
-
Pfizer's Paxlovid racks up a rare trial miss, Medicago and GSK publish positive data for their plant-based particle vaccine and Rhythm Pharmaceuticals touts strong potential in Bardet-Biedl Syndrome.
-
Imago BioSciences Announces Completion of Enrollment in Phase 2 Clinical Study of Bomedemstat in Essential Thrombocythemia
5/3/2022
Imago BioSciences, Inc. (“Imago”) (Nasdaq: IMGO), a clinical stage biopharmaceutical company discovering and developing new medicines for the treatment of myeloproliferative neoplasms (MPNs) and other bone marrow diseases, today announced that enrollment has been completed for the Phase 2 clinical study of bomedemstat for the treatment of essential thrombocythemia (ET) with 73 patients enrolled, exceeding the initial target enrollment of 60 patients.
-
BioSpace Movers & Shakers, March 25
3/25/2022
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
Imago BioSciences Reports Fourth Quarter and Full Year 2021 Financial Results
3/24/2022
Imago BioSciences, Inc. (“Imago”) (Nasdaq: IMGO), a clinical stage biopharmaceutical company discovering new medicines for the treatment of myeloproliferative neoplasms (MPNs) and other bone marrow diseases, today reported financial results for the full year ended December 31, 2021.
-
Imago BioSciences Appoints Michael Arenberg to Chief Operating and Business Officer
3/23/2022
Imago BioSciences, Inc., a clinical stage biopharmaceutical company discovering new medicines for the treatment of myeloproliferative neoplasms, announced the appointment of Michael Arenberg to Chief Operating and Business Officer.
-
Imago BioSciences to Participate in the Cowen 42nd Annual Health Care Conference
2/28/2022
Imago BioSciences, Inc. (“Imago”) (Nasdaq: IMGO), a clinical stage biopharmaceutical company discovering new medicines for the treatment of myeloproliferative neoplasms (MPNs), today announced that Hugh Y. Rienhoff, Jr., M.D., Imago’s Chief Executive Officer, will participate in the Cowen 42nd Annual Health Care Conference.
-
Imago BioSciences to Participate in Guggenheim Healthcare Talks 2022 Oncology Conference
2/4/2022
Imago BioSciences, Inc. announced that Hugh Y. Rienhoff, Jr., M.D., Imago’s Chief Executive Officer, will participate in a fireside chat at the Guggenheim Healthcare Talks 2022 Oncology Conference on Thursday, February 10, 2022 at 10:30 a.m. PT / 1:30 p.m. ET.
-
Omega raised $650 million, which it plans to invest in life science companies in the U.S. and Europe.
-
Imago BioSciences Presents Positive Data from Ongoing Phase 2 Study of Bomedemstat in Essential Thrombocythemia at ASH 2021
12/12/2021
Imago BioSciences, Inc., a clinical stage biopharmaceutical company discovering new medicines for the treatment of myeloproliferative neoplasms, presented positive data from its ongoing global Phase 2 clinical study evaluating bomedemstat in patients with essential thrombocythemia.
-
Imago BioSciences Presents Positive Data from Ongoing Phase 2 Study of Bomedemstat in Advanced Myelofibrosis at ASH 2021
12/11/2021
Imago BioSciences, Inc., a clinical stage biopharmaceutical company discovering new medicines for the treatment of myeloproliferative neoplasms, presented positive data from its ongoing global Phase 2 clinical study evaluating bomedemstat in patients with advanced myelofibrosis.
-
Imago BioSciences to Host Virtual Investor EventCompany to host virtual investor event on Sunday, December 12, 2021 at 11:00 a.m. ET
12/1/2021
Imago BioSciences, Inc. (“Imago” or the “Company”) (Nasdaq: IMGO), today announced that a virtual investor event will be hosted by the company’s management team following the company’s presentations at the 63rd American Society of Hematology (ASH) annual meeting and exposition.
-
Imago BioSciences Appoints Laurie Keating to Board of Directors
11/18/2021
Imago BioSciences, Inc. (Imago) (Nasdaq: IMGO), a clinical stage biopharmaceutical company discovering new medicines for the treatment of myeloproliferative neoplasms (MPNs), today announced the appointment of Laurie Keating to its Board of Directors on November 17, 2021.
-
Imago BioSciences to Present at Stifel 2021 Virtual Healthcare Conference
11/11/2021
Imago BioSciences, Inc. (“Imago”) (Nasdaq: IMGO), a clinical stage biopharmaceutical company discovering new medicines for the treatment of myeloproliferative neoplasms (MPNs), today announced that Hugh Y. Rienhoff, Jr., M.D., Imago’s Chief Executive Officer, will present at the Stifel 2021 Virtual Healthcare Conference.
-
Imago BioSciences Reports Third Quarter 2021 Financial Results and Provides Recent Business Updates
11/10/2021
Imago BioSciences, Inc. (“Imago”) (Nasdaq: IMGO), a clinical-stage biopharmaceutical company discovering new medicines for the treatment of myeloproliferative neoplasms (MPNs), today reported financial results for the third quarter ended September 30, 2021 and highlighted recent corporate updates.
-
Imago BioSciences Announces Oral Data Presentations at the Upcoming 63rd American Society of Hematology Annual Meeting and Exposition
11/4/2021
Imago BioSciences Announces Oral Data Presentations at the Upcoming 63rd American Society of Hematology Annual Meeting and Exposition
-
Imago BioSciences Announces Its Addition to the Russell 2000® Index
9/20/2021
Imago BioSciences , Inc. today announced that it will be added to the Russell® 2000 Index as part of the planned second quarter IPO additions scheduled to join the Russell US Indexes on September 20, 2021.